Menu Close

Tag: 2023 News

Auditor Suggest State Bar Improve Integrity of Attorney Probes

According to a new audit released this week by California State Auditor Grant Park, the State Bar of California must act to protect the integrity of its attorney investigations and slow a spending deficit that could cripple its operations.

The State Bar’s Office of the Chief Trial Counsel is responsible for investigating and prosecuting complaints against attorneys. However, if a conflict of interest related to a complaint could raise concerns about the Office of the Chief Trial Counsel’s impartiality, the chief trial counsel must refer that complaint to a special deputy trial counsel administrator (administrator) – an independent contractor who has all the powers and duties of the chief trial counsel.

A team of about 20 special deputy trial counsels (external investigators), who are also independent contractors, support the administrator in investigating and prosecuting external disciplinary cases.

Although the State Bar tracks centralized data related to such cases through its case management system, the audit found multiple errors and omissions in these data, impeding its ability to effectively monitor external investigations. The audit also found that external investigators did not consistently conclude their investigations within six months.

Finally, the State Bar has not formalized its process to ensure that its external investigators are free from conflicts of interest.

With regard to budgetary issues, the Auditor said that in recent years, the State Bar has often spent more from its general fund than it has received in revenue.

The State Bar deposits the majority of its mandatory licensing fee revenue into its general fund, and it then uses this fund to pay for its administrative offices and nine of its 11 public protection programs. The State Bar’s personnel costs have recently increased and will continue to increase in the coming years.

Further, none of the State Bar’s administrative offices are fully meeting their performance measures, likely in part because some have high staff vacancy rates.

The State Bar operates 16 major programs. These programs address different aspects of its mission, such as investigating and prosecuting attorneys for rules violations, administering the California bar exam, and promoting diversity and inclusion in the legal system. In addition to its 16 major programs, the State Bar also has 10 administrative offices that provide support to all State Bar activities.

Although the State Bar will need a mandatory fee increase in 2024, it can minimize this increase and other future increases by raising other fees it charges for providing certain services to fully cover the associated costs and updating other out-of-date fees.

The State Bar is considering whether some programs serve a public protection function that supersedes the need for them to be self-sufficient, meaning that it may decide not to raise all of these fees. In particular, according to the chief financial officer (CFO), the State Bar believes that increasing fees for its Mandatory Fee Arbitration program and Lawyer Referral Service program (both service fees) could result in the public using these programs less.

State Bar staff recommended changes to the LLPs program’s fees that would generate from $500,000 to more than $700,000 annually and changes to the Law Corporations program’s fees that would generate more than $300,000 annually in addition to the current fee revenues generated by the programs. The State Bar is in the process of soliciting feedback from impacted parties on the appropriate fee level for LLPs.

The State Bar owns two buildings – one in San Francisco and the other in Los Angeles. Based on recent estimates, the State Bar occupies about 60 percent of its San Francisco space and about 80 percent of its Los Angeles space. It leases out the remaining space in both buildings.

The State Bar is in the process of trying to sell its San Francisco building. If it is able to do so, it could realize significant savings, particularly given that the ownership costs for the building have increased in recent years.

In 2021 the State Bar spent nearly $5.7 million on both capital improvements and building operations for its San Francisco building, and estimates its 2022 costs were nearly $5.6 million. The State Bar projects that it could save an average of more than $4 million annually in building operating expenses alone if it sells the building.

The State Bar intends to present all of its recommended fee increases to its board in May 2023. If it is able to raise these fees, it could make improvements to these programs and to other disciplinary or regulatory programs without needing to spend mandatory licensing fee revenue to do so.

The State Bar agreed with all of the Auditor’s recommendations, but included what it referred to as additional contextual information in its response. The State Bar also indicated its willingness to work with the Legislature to implement all of the recommendations.

Is New CRISPR Technology Drug Cost Effective at $1.9M for a Single Dose?

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.

The Institute just released a 113 page Draft Evidence Report assessing the comparative clinical effectiveness and value of exagamglogene autotemcel (“exa-cel”, Vertex Pharmaceuticals and CRISPR Therapeutics) and lovotibeglogene autotemcel (“lovo-cel”, bluebird bio) for sickle cell disease. This preliminary draft marks the midpoint of ICER’s eight-month process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.

The world’s first CRISPR-based gene-editing therapy appears to be nearing the market. And an influential drug cost watchdog has an early idea of how the treatment should be priced to be considered cost-effective in sickle cell disease (SCD).

Vertex and CRISPR Therapeutics’ gene editing-based exa-cel – and bluebird bio’s gene replacement therapy lovo-cel – can be priced up to $1.93 million to be cost-effective, the Institute for Clinical and Economic Review said in a draft report (PDF) published Wednesday. The figure accounts for the drugs’ net prices after discounts and rebates.

The report comes shortly after Vertex and CRISPR last week said they had completed their rolling FDA applications for exa-cel in SCD and beta thalassemia with a request for priority review. If approved, exa-cel would become the first therapy based on the Nobel-winning CRISPR technology.

Sickle cell disease can affect nearly every organ system in the body, and severe sickle cell disease affects nearly every aspect of a person’s life,” said ICER’s Chief Medical Officer, David Rind, MD. “From the earliest days of gene therapy, patients, families, and clinicians have imagined that someday it might be possible to address the underlying genetics of sickle cell to achieve a cure. These first two genetic therapies, using different technologies and altering different genetic targets may mean that day has nearly arrived.”

The prevalence of sickle cell disease is unknown, but CDC estimates place it at about 100,000 cases in the U.S. It is a blood disease that can spur chronic complications among all organs, and annual healthcare costs rack up to $2.98 billion, the ICER said.

The model developed to generate cost-effectiveness findings in ICER’s draft report used cutting-edge evidence from academic researchers and was informed by what matters to patients.  

Through collaborative input from patients, clinicians, health economists, payers, and manufacturers, ICER’s draft model not only includes the projected health benefits and cost offsets from reducing the acute events as measured in the clinical studies but also includes the projected benefits from eliminating the fear of future acute events, reductions in chronic events and mortality, health equity considerations, and reductions in lost productivity and caregiver burden.

Two proposed gene therapies for sickle cell disease (SCD) are each worth up to $1.9 million, according to an April 12 draft evidence report from the Institute for Clinical and Economic Review.Given that both gene therapies offer the promise of a potential cure, ICER compared them with standard of care over a lifetime.

The health economics reviewers figured the two therapies could cost between $1.58 million to $1.72 million under commonly used cost-effectiveness thresholds that only look at benefits within the healthcare system. The range goes up to between $1.79 million to $1.93 million when considering broader societal value.

Gene therapies typically cost multiple millions of dollars per treatment. Bluebird recently launched Zynteglo, a sister med to lovo-cel, at $2.8 million. Zynteglo is approved for beta thalassemia, a rare blood disorder that affects about 1 in 100,000 individuals.

It’s not immediately clear how bluebird or Vertex-CRISPR will price their therapies. A Vertex spokesperson said the company is still reviewing the report. In a separate statement, a bluebird spokesperson said the company hasn’t set a price for lovo-cel and is currently focused on completing its FDA application.

During an interview with Fierce Pharma, ICER’s chief medical officer, David Rind, M.D., stressed that the cost-effectiveness analyses are preliminary and may change. ICER is gathering public comments until May 9 and pushed back its final report publish date to July 13 in anticipation of more data on exa-cel.

Aggressive Marketing Pays Off For Specialty Drugmaker

Horizon Therapeutics says it now has 20 drugs under development, in its 15 years of existence it has yet to license a product it invented. Yet the company has managed to assemble a war chest of lucrative drugs, in the process writing a playbook for how to build a modern pharmaceutical colossus.

As the White House and both parties in Congress grapple with reining in prescription drug prices, a report in KFF News says that Horizon’s approach reveals just how difficult this may be.

Horizon’s strategy has paid off handsomely. Krystexxa was just one of the many shiny objects that attracted Amgen, a pharmaceutical giant. Amgen announced in December that it intends to buy Horizon for $27.8 billion, in the biggest pharmaceutical industry deal announced in 2022. Krystexxa brought in $716 million in 2022 and was expected to earn $1 billion annually in coming years.

According to the KFF report, Horizon’s CEO, Tim Walbert, who will reportedly get around $135 million when the deal closes, has mastered a particular kind of industry expertise: taking drugs invented and tested by other people, wrapping them expertly in hard-nosed marketing and warm-hued patient relations, raising their prices, and enjoying astounding revenues.

He’s done this with unusual finesse – courting patients with concierge-like attention and engaging specialist clinicians with lunches, conferences, and research projects, all while touting his own experience as a patient with a rare inflammatory disease. Walbert’s company has been particularly adept at ensuring that insurers, rather than patients, bear the costly burdens of his drugs.

KFF News reported that a federal prosecutor in 2015 began examining allegations that Horizon’s patient assistance program had worked with specialty pharmacies to evade insurers’ efforts to shun Horizon’s expensive drugs. A separate probe opened in 2019 over alleged kickbacks to pharmacy benefit managers, companies that negotiate to get Horizon’s drugs covered by insurers. Those investigations appear to be no longer active, Horizon spokesperson Catherine Riedel said.

The company this year disclosed a third probe, concerning methods the company allegedly used to get prior authorization of its drugs. Justice officials did not respond to requests for comment on the investigations.

To help sell its drugs, Horizon blankets specialist physicians with marketing and peer-to-peer appeals. Its payments to physicians for things like consulting, speeches, and meals totaled $8.7 million in 2021, compared with the $10 million it paid them for research, federal records show.

By contrast, Seagen, a biotech company of roughly the same size, paid doctors a total of $116 million, with nearly $112 million of that pegged for research. Riedel said Horizon’s marketing and educational approaches were “necessarily unique” because of the challenges of treating rare and neglected diseases.

While at Abbott, Walbert pioneered direct-to-consumer advertising for specialty drugs like Humira, a trend that aggravated insurers, who anticipated, correctly, that they would soon be shelling out billions for expensive drugs.

The company defends its marketing practices. “We learn what matters most to patient communities and act. This approach has been validated by independent third-party research,” said Riedel.

The Federal Trade Commission said in January it was seeking more information on the Amgen-Horizon merger. Sen. Elizabeth Warren (D-Mass.), citing high prices for Horizon and Amgen drugs, urged the agency to nix the deal.

California Chamber of Commerce Published 2023 List of “Job Killer Bills”

Each year the California Chamber of Commerce releases a list of job killer bills to identify legislation that it says will decimate economic and job growth in California. Earlier this month, CalChamber released its 2023 Job Killer List which includes bills dealing with labor and employment issues, taxation, housing costs, and climate and energy policies, and it expects several additions to the list in the coming weeks.

The CalChamber has named the following as job killer bills for 2023 under the category of Labor and Employment, along with it’s summary of the impact on employers and jobs that they expect.

– – AB 524 (Wicks; D-Oakland) Expansion of Litigation Under FEHA. Exposes employers to costly litigation under the Fair Employment and Housing Act by asserting that any adverse employment action was in relation to the employee’s family caregiver status, which is broadly defined to include any employee who contributes to the care of any person of their choosing, and creates a de facto accommodation requirement that will burden small businesses.

– – AB 1156 (Bonta; D-Alameda) Expands Costly Presumption of Injury. Significantly increases workers’ compensation costs for public and private hospitals by presuming certain diseases and injuries are caused by the workplace and establishes an extremely concerning precedent for expanding presumptions into the private sector.

– – SB 525 (Durazo; D-Los Angeles) Costly Minimum Wage Increase. Imposes significant cost on health care facilities and any employer who works with health care facilities by mandating increase in minimum wage to $25.

– – SB 365 (Wiener: D-San Francisco) Undermines Arbitration. Discriminates against use of arbitration agreements by requiring trial courts to continue trial proceedings during any appeal regarding the denial of a motion to compel, undermining arbitration and divesting courts of their inherent right to stay proceedings.

– – SB 399 (Wahab; D-Hayward) Bans Employer Speech. Chills employer speech regarding religious and political matters, including unionization. Is likely unconstitutional under the First Amendment and preempted by the National Labor Relations Act.

– – SB 616 (Gonzalez; D-Long Beach) Costly Sick Leave Expansion on All Employers. Imposes new costs and leave requirements on employers of all sizes, by more than doubling existing sick leave mandate, which is in addition to all other enacted leave mandates that small employers throughout the state are already struggling with to implement and comply.

– – SB 627 (Smallwood-Cuevas) Onerous Return to Work Mandate. Imposes an onerous and stringent process to hire employees based on seniority alone for nearly every industry, including hospitals, retail, restaurants, movie theaters, and franchisees, which will delay hiring and eliminates contracts for at-will employment.

– – SB 723 (Durazo; D-Los Angeles) Onerous Return to Work Mandate. Imposes an onerous and stringent process for specific employers to return employees to the workforce for specified industries, including hotels and restaurants that have been disproportionally impacted by this pandemic, and removes guardrails on existing law by making mandate permanent and significantly broadening the applicability of the law.

– – SB 809 (Smallwood-Cuevas; D-Los Angeles) Prohibits Consideration of Conviction History in Employment. Prohibits nearly every employer from considering conviction history of an applicant or existing employee in employment decisions and imposes cumbersome process on employers that are legally not allowed to hire individuals with certain convictions.

“California’s robust private sector economy creates and maintains more than 17 million jobs, paying $1.6 trillion in annual wages and salaries,” said CalChamber President and CEO Jennifer Barrera. “Yet, cost pressures, workforce challenges, litigation threats, and California’s pernicious housing shortage are an ever-present threat to our continued success. Costly policies – like the ones on CalChamber’s job killer list – stifle job creation, reduce investment in our economy, and drive outward migration. Job killing policies make California unattractive both to current employers and entrepreneurs who, incidentally, generate the preponderance of the state’s tax revenue, and to those who might want to come here to invest in our future economy.”

The CalChamber tracks the bills throughout the rest of the legislative session and works to educate legislators about the serious consequences these bills will have on the state. Over the last five years, the outcome of bills on the past Job Killer Lists were as follows:

– – 2022: 19 Job Killers identified, 2 sent to Governor Gavin Newsom, 2 signed;
– – 2021: 25 Job Killers identified, 2 sent to Governor Newsom, 1 signed, 1 vetoed;
– – 2020: 19 Job Killers identified, 2 sent to Governor Newsom, 1 signed, 1 vetoed;
– – 2019: 31 Job Killers identified, 2 sent to Governor Newsom, 1 signed, 1 vetoed;
– – 2018: 29 Job Killers identified, 1 sent to Governor Edmund G. Brown Jr., 1 vetoed;
– – 2017: 27 Job Killers identified, 3 sent to Governor Brown, 2 signed, 1 vetoed;

Five Defendants Face WorkComp Premium Fraud Charges

Five defendants were recently arraigned on multiple felony counts of insurance fraud after a California Department of Insurance investigation found the landscaping company the defendants owned and/or supervised allegedly underreported employees’ wages to their insurance company in order to unlawfully save on workers’ compensation insurance premiums.

Three defendants include Antonio Martinez Resendiz of Murrieta, Ismael Martinez Resendiz of Fallbrook, and Jorge Martinez Resendiz of Temecula, owners of Green View Landscape & Tree Service Inc. in Escondido.

The two additional defendants are Ariana Martinez of Murrieta, and Silvia Reyna Martinez of Temecula, supervisors within the company.

Employers are required to maintain workers’ compensation insurance to cover their employees in the event of an on-the-job injury. To ensure proper coverage, employers are required to accurately report their employees’ job classifications and the amount of payroll expended. One of the common ways in which employers avoid paying insurance premiums is to underreport employee payroll by providing false payroll reports to their insurance company.

Businesses that fraudulently lower their premiums benefit from an unfair market advantage, giving them the ability to charge less in labor costs, and thereby underbid businesses who pay the appropriate premiums.

The San Diego County District Attorney’s Office is prosecuting this case.

San Diego Surgeon Faces Murder Charges following Patients Death

48 year old Carlos Orlando Chacon M.D., was initially charged in late 2021 with involuntary manslaughter and other charges, along with Heather Vass, one of his nurses, in the death of Megan Espinoza, a 36-year-old mother of two who died more than a month after undergoing a breast augmentation operation at Divino Plastic Surgery in Bonita, California on Dec. 19, 2018.

San Diego County Prosecutors said Espinoza was provided anesthesia by Vass, a nurse who was not trained to do so. The patient went into cardiac arrest during the operation and Chacon allegedly delayed contacting emergency services for about three hours.

Chacon was previously released on his own recognizance under a number of conditions, but was arrested and jailed last week. Years after he was charged with involuntary manslaughter in the death of the 36-year-old mother of two, California authorities have now charged Dr. Chacon with second-degree murder for Megan’s death.

Deputy District Attorney Gina Darvas said Monday that further investigation into the case yielded additional information that led to the filing of the murder charge, including allegations that Chacon ordered his staff not to call 911 when Espinoza’s condition declined and that he instructed staff to lie to Espinoza’s husband regarding her condition.

The April 6, 2023 probable cause warrant outlines the results of the investigation the Medical Board of California provided the San Diego County District Attorney’s Office, and what further investigation disclosed about the death. A complaint was filed with the Medical Board by one of the paramedics who transporter Espinoza because of concerns that Dr. Chacon had waited almost 3 hours to call 911 to request emergency medical assistance, which is standard protocol when CPR is performed, as defined by the American Heart Association.

Court documents claim that Chacon did not contact 911 to request emergency assistance until approximately 3 hours after Espinoza’s cardiac arrest. Paramedics arrived and Espinoza was transported to Scripps Hospital, in Chula Vista.

Upon her arrival at the hospital, doctors intubated Espinoza to establish a secure airway and placed her on a ventilator. Doctors discovered she had a pressure induced pneumothorax as a result of prolonged and aggressive bagging. Espinoza had also sustained undue stress to her heart as a result of the prolonged bagging.

Espinoza was admitted to the Intensive Care Unit of Scripps Hospital. A chest tube was inserted and over the next five days Espinoza’s pulmonary function improved. However, her neurological function remained critical.

Espinoza was transferred to UCSD Medical Center’s Neurological Intensive Care Unit, where her condition continued to deteriorate. Physicians notified Espinoza’s husband and mother that she was not expected to regain neurological function. The family chose to place Espinoza on palliative/compassionate care.

Espinoza never regained consciousness, or the ability to breath on her own. Espinoza passed away on 01/28/19. An autopsy was performed. The autopsy determined the cause of death to be, “lschemic Encephalopathy due to resuscitated cardiac arrest following anesthesia for elective surgery.” lschemic Encephalopathy is defined as a brain dysfunction caused by a lack of blood flow and oxygen to the brain.

Two medical experts were consulted by the Medical Board. Both provided the opinion that Dr. Chacon’s handling of Espinoza’s surgical procedure was an extreme departure or deviation of the standard of care.

The District Attorney’s Office investigation continued after the original charges were brought. This lead prosecutors to claim that “Chacon began a pattern of conscious disregard for human life prior to beginning Megan Espinoza’s surgery.” and that as a result “probable cause exists to believe Chacon is allegedly guilty of PC 187(a) Second Degree Murder with Malice Aforethought.”

Mr. Espinoza stated in sworn testimony, in the related civil case, that he had been present when Mrs. Espinoza discussed anesthesia with Chacon. Chacon told Mrs. Espinoza that an anesthesiologist who had privileges with two different Sharp Hospital locations would be coming to Divino to provide the anesthesia, which was not what happened.

The transcript of Chacon’s sworn testimony during the civil deposition revealed that Chacon admitted Heather Vass administered the anesthesia, and that he did not specifically direct Nurse Vass what medications and dosages she should administer to Espinoza during the surgery. Instead, Chacon provided Vass with a two-page chart that listed drugs and dosage amounts that Vass could use during every surgery in which she provided anesthesia services for Chacon.

Vass confirmed in her deposition that Chacon did not give her any verbal or written instructions regarding any of the medication and dosages she charted on the Nursing Note. She independently made those decisions.

Dr. Michael Dinh and Dr. Jesus Lozano, were two anesthesiologists whom Chacon contacted by phone for advice after Espinoza’s cardiac arrest. When prosecutors interviewed Dr. Dinh, they were told that a registered nurse is not allowed to pick and choose the drugs and dosages and administer them to a patient. They can only act upon a physician’s orders that are tailored to the specific patient’s needs.

Investigators noted that videos taken by Chacon during Espinoza’s surgery showed that Chacon used a sterile drape, which blocked Chacon’s view of what Heather Vass was doing during the surgery. And witness Zenia De Los Santos, who was in the surgical room during Espinoza’s procedure, stated Chacon was playing loud music during the procedure that made it difficult for anyone in the room to hear what the others were saying, or to hear any auditory warnings from the surgical monitor.

Prosecutors say Chacon did not call 911 until 3 hours after Espinoza’s heart stopped. During that time, Vass was using the Ambu bag to assist Espinoza with her breathing. She never regained consciousness.

Coworker, Zenia De Los Santos, described ineffective efforts at resuscitation, and about feeling overwhelmed and abandoned by Chacon who left the operating room for prolonged periods of time during the three hour resuscitation effort. She claims she and her coworkers were told by Chacon not to call 911 until instructed to do so. De Los Santos also told investigators that finally at 5:00 the office was ready to close, and about 30 minutes later, after everyone was gone, the ambulance arrived. By then, it was much too late to save her.

Chacon allegedly saw at least four other patients in the hours after Espinoza’s cardiac arrest but before he called 911 at 5:24 p.m. and was described as acting “robotic” during that time-frame – “as if he wasn’t concerned,” as the warrant put it. Nor did he tell Megan Espinoza’s husband about her condition until 5:41 p.m., documents alleged.

The warrant concluded that Chacon had displayed the kind of deliberate inaction with conscious disregard for human life required for a charge of second-degree murder committed with implied malice.

His criminal defense attorney Marc Carlos told a local news station that the charges against Chacon are unsupportable.

In December 2022, KGTV reported that Megan’s family had reached a settlement in a lawsuit against Chacon.

12 Suspects Face 110 Felonies in Disability Insurance Fraud Scheme

The California Attorney General and the Department of Insurance announced charges have been filed against 12 individuals in Southern California, for their alleged involvement in a disability fraud scheme. They face over 110 felony counts including conspiracy, insurance fraud, and grand theft, for their alleged involvement in a disability fraud scheme.

The lead suspects, a husband and wife from Rancho Cucamonga, allegedly defrauded the Covid-19 Relief Program and applied, through fake employers, for supplemental short-term disability policies offered by private insurance carriers, such as Aflac, Allstate, Colonia and Combined.

The Department of Insurance opened an investigation in April of 2020 after receiving several suspected fraud referrals from multiple insurance carriers claiming numerous individuals applied for disability insurance policies using fraudulent information or filed fraudulent disability claims using fraudulent information.

Department detectives conducted numerous search warrants and interviews and determined the alleged ringleaders used ‘shell’ companies to apply for short-term group disability policies offered by private insurance carriers and through the COVID-19 Relief Program.

They would then recruit individuals to be fictitious employees and would file fraudulent disability claims under those fictitious employees.

This alleged fraud scheme resulted in a loss of approximately $458,732 to the insurance carriers. The ringleaders collected most of the profit from the scheme and would give those they recruited a percentage of the proceeds for their participation.

Suspects were arrested throughout the state on Thursday, April 6, 2023, and Friday, April 7, 2023.

“These suspects allegedly used false companies and fictitious employees to take advantage of a system designed to help injured workers,” said Insurance Commissioner Ricardo Lara. “These types of schemes negatively impact consumers and businesses through higher costs. We will continue to work with our law enforcement partners to protect consumers and combat insurance fraud.”

“Crimes against a program like the state’s short-term disability fund, which is designed to provide relief to injured Californians by providing them with financial assistance during trying times, will not be tolerated,” said Attorney General Rob Bonta. “Those who steal from these programs are stealing from the families who rely on them. My office will vigorously pursue anyone who commits fraud against these critical programs.”

The Office of the Attorney General is prosecuting the case.

O.C. Restaurant Loses Battle For COVID Closure Insurance Coverage

Coast Restaurant Group, Inc. operates the Cedar Creek Inn, a restaurant in North Orange County, which offers a variety of fine food, an extensive wine list and craft beer, and live musical performances from Tuesday through Saturday.

It obtained business interruption insurance from AmGUARD Insurance Company, covering the period from March 30, 2019 to March 30, 2021. Business interruption insurance “protects against the loss of income and other losses caused by an interruption to the normal operations of the business.”

On March 17, 2020, the Orange County health officer issued an order that, among other things, “prohibited restaurants from serving food on their premises and prohibited all gatherings of people.” The next day, the county health officer issued an amended health order and guidance requiring “[a]ll restaurants and other business establishments that serve food shall close all onsite [sic] dining.”

The Restaurant submitted a claim for its business income loss. The was denied by AmGUARD Insurance Company.

Coast Restaurant Group subsequently filed a lawsuit against their carrier. The First Amended Complant (FAC) asserted that the restaurant “did not lose any business income as a result of virus contamination,” but rather its “losses of business income were caused by, and a direct result of, government stay-at-home orders in California.” The Restaurant attached a copy of the insurance policy and also attached the governmental orders restricting on-site gatherings at restaurants to its FAC.

The carrier demurred to the FAC. contending that the insurance policy does not cover “losses arising from the COVID-19 virus, including government[al] directives issued in response to the virus.”

Separately, respondent contended that appellant did not allege any “direct physical loss or damage to” the covered property because governmental orders limiting the use of respondent’s property do not amount to “direct physical loss of or damage to property.” Respondent further asserted the “Ordinance or Law” exclusion precludes coverage for “losses arising from government-imposed use restrictions.”

The trial court sustained the demurrer without leave to amend. The Court of Appeal affirmed in the published case of Coast Restaurant Group, Inc. v. AmGUARD Insurance Company – G061040 (April 2023).

In essence, the Court of Appeal concluded that Coast Restaurant has shown there is potential coverage under the policy, but AmGUARD Insurance Company has shown that an exclusion in the policy applies to preclude coverage as a matter of law.

While physical alteration to covered property could trigger coverage under a “physical loss or damage” insuring provision, that is not the only possible trigger for coverage. Deprivation or dispossession also would trigger coverage, even if the property has not been physically altered.

However, under the ordinance or law exclusion, “loss or damage caused directly or indirectly by . . . enforcement of any ordinance or law . . . [that regulates] the construction, use or repair of any property” are not covered.

The governmental orders at issue clearly regulate the use of covered property by prohibiting on-site dining. Accordingly, the ordinance or law exclusion would apply to preclude coverage.

In the alternative, the virus exclusion applies to deny Coast Restaurant Group coverage for its business income loss. The policy does not cover “loss or damage caused directly or indirectly by” “[a]ny virus, bacterium or other microorganism that induces or is capable of inducing physical distress, illness or disease.”

Thus the Court of Appeal concluded that, at a minimum, COVID-19 triggered the governmental orders and it “indirectly” caused appellant’s business income loss. The virus exclusion thus applies here.

Newsom v Wallgreens – Walgreens Seems to Be Winning (So Far)

On March 6, Gov. Gavin Newsom tweeted that “California won’t be doing business with Walgreens,” because of the company’s decision to not distribute an abortion pill in states that banned the medication.

“California will not stand by as corporations cave to extremists and cut off critical access to reproductive care and freedom,” Newsom said in a news release. “California is on track to be the fourth largest economy in the world and we will leverage our market power to defend the right to choose.”

The contract between the California Department of General Services (DGS) and Walgreens allows the State to procure specialty pharmacy prescription drugs, primarily used by the California Department of Corrections and Rehabilitation (CDCR) and its correctional health care system.

At Governor Newsom’s directive, DGS gave formal notice that it is withdrawing a planned renewal of that agreement set to take effect on May 1, 2023, and instead will explore other options for furnishing the same services. Under this contract, Walgreens has received about $54 million from the State. This contract with Walgreens was to purchase specialty pharmacy prescription drugs for California’s prison health care system, including antiviral and antifungal drugs and medication used for congestive heart failure

As CalMatters’ Kristen Hwang and Ana Ibarra reported, there are about 600 Walgreens stores in California, making up 10% of the state’s pharmacy market. And it was such a vital prescription provider for Medi-Cal insurers that store locations were listed on the state’s pharmacy directory for enrollees.

But as California Healthline reported Thursday, it appears that the governor’s proposal isn’t going to have as dramatic an impact on Walgreens as initially thought.

Walgreens is allowed to rebid on the contract Newsom said the state wouldn’t renew, and California paid Walgreens a total of $1.5 billion last year.

It is also “legally bound to continue doing business with Walgreens through the state’s massive Medicaid program.”

CalMatters said that it’s unclear what approach Newsom and his staff will take going forward – his office did not respond to a request for comment on Thursday. But if the governor continues his “panache for sweeping announcements” as California Healthline put it, his national profile will continue to rise as well.

USA Today reports that Walgreens was “deeply disappointed by the decision by the state of California not to renew our longstanding contract due to false and misleading information,” said representative Fraser Engerman.

Walgreens is facing the same circumstances as all retail pharmacies, and no other pharmacies have said that they would approach this situation differently, so it’s unclear where this contract would not be moved,” Engerman said. “Our position has always been that, once we are certified by the FDA, Walgreens plans to dispense Mifepristone in any jurisdiction where it is legally permissible to do so, including the state of California.”

Walgreens said last week it assured 20 attorneys general that it would not dispense the pill in their states after the group sent a letter threatening the company with legal action. Abortion is legal in many of these states, including Kansas, Alaska, Iowa and Montana.

The company issued a statement Monday saying it would dispense the pill “where it is legally permissible” but did not respond to a request for comment on whether that included states with attorneys general who threatened legal action.

“We want to be very clear about what our position has always been: Walgreens plans to dispense Mifepristone in any jurisdiction where it is legally permissible to do so. Once we are certified by the FDA, we will dispense this medication consistent with federal and state laws. Providing legally approved medications to patients is what pharmacies do, and is rooted in our commitment to the communities in which we operate.”

Homeowner is Employer of Uninsured Licensed Contractor’s Worker

Kenneth Harlan was employed by Affordable Plumbing and Rooter for six or seven months until he was injured on August 3, 2010 while performing plumbing work at a new construction project, in Torrance California. He was injured while capping a sewage pipe that was placed in a three foot trench. He was paid in cash, depending on the type of job.

Hiroshi Tange was the homeowner who owned the property in Torrance, and had a homeowners policy of insurance with Farmers at the time of this injury.

During the first day of trial, Affordable was shown to have a Contractor’s License but was uninsured for workers’ compensation. With this additional information the case was set for second day of trial.

Hiroshi Tange, the homeowner testified that he had no recollection of seeing applicant work at the property at any time. He did not hire a plumbing contractor. The plumbing work was done by his brother-in-law, a handyman, who was not a licensed contractor, and a tile setter. The handyman did most of the plumbing under the house. The homeowner could not recall who dug the trench and laid the pipe to the sewer which was being capped by applicant.

The WCJ found that Harlen was an employee of the homeowner, Hiroshi Tang, at the time of the injury. Farmers Insurance and Hiroshi Tange petitioned for Reconsideration which was denied for the reasons stated in the WCJ’s report, which was adopt and incorporated in the panel decision of Harlan v Affordable Plumbing – ADJ7507358 (April 2023)

In his Report the WCJ noted that the type of work being performed (Plumbing) requires a license in good standing in California (Business and Professions Code Section 7000 et. seq.).

A contractor’s license is suspended, as a matter of law, at the time of hire of an employee in the absence of compensation insurance (Labor Code Section 3700; Business and Professions Code Section 7125.2).

The burden of proof on an issue lies with the party having the affirmative of the issue (Labor Code Sec. 5705). The applicant has the affirmative on the issue of employment and must prove the elements by a preponderance of the evidence.

Labor Code Section 2750.5 provides in pertinent part as follows: “There is a rebuttable presumption affecting the burden of proof that a worker performing services for which a license is required pursuant to Chapter 9 (commencing Section 7000) of Division 3 of the Business and Professions Code, or who is performing such services for a person who is required is an employee rather than an independent contractor…”

The WCJ noted that “Applicant’s testimony is more plausible than that of the homeowner on several points. … None of the work being done on the construction site was performed by contractors who were insured for workers’ compensation. … Review of this record shows that the testimony of the applicant has a greater likelihood of truth than that of the homeowner.”

Thus the WCJ concluded that “Affordable was doing work which required an active license. The license was suspended due to the lack of workers’ compensation insurance. As an employee of the unlicensed contractor Harlan is presumed to be the employee of the person or persons who benefitted by his labor and has control over the project” citing (Laeng v. Workmen’s Comp. Appeals Bd. (1972) 6 Cal. 3d 774 37 CCC 185).

The WCAB panel agreed with this conclusion stating “We have given the WCJ’s credibility determination great weight because the WCJ had the opportunity to observe the demeanor of the witnesses. (Garza v. Workmen’s Comp. Appeals Bd. (1970) 3 Cal.3d 312, 318-319 [35 Cal.Comp.Cases 500].) Furthermore, we conclude there is no evidence of considerable substantiality that would warrant rejecting the WCJ’s credibility determination(s).”